Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Xiangyu Zhang, Liang Zeng, Yizhi Li, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 9, pp. 2517-2528
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
Tianyao Lei, Tianwei Xu, Niu Zhang, et al.
Pharmacological Research (2023) Vol. 188, pp. 106668-106668
Open Access | Times Cited: 34
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
Na Zhou, Man Jiang, Tianjun Li, et al.
Lung Cancer (2021) Vol. 160, pp. 111-117
Closed Access | Times Cited: 33
Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy
Peng Fan, Huiping Qiang, Zhenhua Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer
Li Liu, Shuo Zhang, Haiyan Yang, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction
Linfeng Li, Qidong Cai, Zeyu Wu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 13
Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study
Lian Yu, Jianlin Xu, Rong Qiao, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 5, pp. 1108-1121
Open Access | Times Cited: 11
Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
Danming He, Lu Wang, Jiachen Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment
Tingfei Tan, Siyu Yuan, Weiwei Chu, et al.
Anti-Cancer Drugs (2025)
Closed Access
An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma
Liyuan Dong, Yue Ma, Guangwen Cao, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study
Xiaoteng Ma, Xiaoyan Yin, Lulu Zhuang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report
Xiaolan Xiang, Waner Lin, Xiaoying Guan, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 5, pp. 2571-2579
Open Access | Times Cited: 3
Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study
Jianyun Jiang, Bin Wu, Ying Sun, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 3
Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
Tianqing Chu, Wei Zhang, Bo Zhang, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 7, pp. 1394-1404
Open Access | Times Cited: 14
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Shumin Yuan, Ling Peng, Yuqing Liu, et al.
Cancer Immunology Immunotherapy (2022) Vol. 72, Iss. 2, pp. 437-448
Closed Access | Times Cited: 14
Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
Peng Sun, Yu Wang, Hang Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Current status and future of anti-angiogenic drugs in lung cancer
Yan Xuan, Zhangyan Zhao, Haicheng Tang
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 6, pp. 2009-2023
Closed Access | Times Cited: 7
Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma
Qiang Guo, Chuangyan Wu, Ni Jiang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy
Yaofei Jiang, Chun Chen, Guoying Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
Changgong Zhang, Jianhua Chen, Huijuan Wu, et al.
Cancer Pathogenesis and Therapy (2024) Vol. 2, Iss. 4, pp. 268-275
Open Access | Times Cited: 2
Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
Yanyan Hao, Yi-Peng Qiao, Jian-De Cheng
International Journal of General Medicine (2021) Vol. Volume 14, pp. 10483-10493
Open Access | Times Cited: 16
Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
Wenxian Wang, Lan Shao, Yibing Xu, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study
Bin Zhou, Qiang Gong, Ben Li, et al.
Journal of Clinical Pharmacy and Therapeutics (2022) Vol. 47, Iss. 5, pp. 643-651
Closed Access | Times Cited: 10
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
Yating Zhao, Liu Liu, Liang Weng
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 14
Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis
Kinnosuke Matsumoto, Takayuki Shiroyama, Tomoki Kuge, et al.
Lung Cancer (2021) Vol. 162, pp. 175-184
Closed Access | Times Cited: 14
Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
Qing Chen, Yan Li, Wenjie Zhang, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 148, Iss. 2, pp. 401-408
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top